Form 4: Veracyte Director Exercises Options, Sells Shares

Veracyte Director Karin Eastham exercised stock options and subsequently sold a portion of her common stock holdings on December 5, 2025, under a Rule 10b5-1 plan.

Summary

• Karin Eastham, a Director of Veracyte, Inc. (VCYT), engaged in a series of transactions on December 5, 2025, pursuant to a Rule 10b5-1 plan adopted on September 5, 2025.
• Eastham exercised stock options to acquire a total of 20,000 shares of common stock: 10,000 shares at an exercise price of $7.94 per share and another 10,000 shares at $7.60 per share.
• Concurrently, Eastham sold a total of 20,000 shares of common stock in multiple transactions.
• The sales included 6,392 shares at a weighted average price of $44.5199, 12,808 shares at a weighted average price of $45.837, and 800 shares at a weighted average price of $46.5898.
• Following these transactions, Karin Eastham's direct beneficial ownership of Veracyte common stock stands at 13,554 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive for the insider, reflecting the realization of significant gains through pre-planned transactions. For the company, it's largely neutral as it's a routine insider transaction under a 10b5-1 plan, not indicative of operational performance.

Positives

• The director realized a significant profit from the exercise of stock options and subsequent sale of shares, demonstrating personal financial gain from her tenure.
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating a structured approach to managing personal holdings and mitigating concerns about opportunistic insider trading.

Negatives

• The director's net sale of 20,000 shares, while part of a plan, results in a reduction of her direct beneficial ownership from 33,554 shares (after option exercises) to 13,554 shares, which could be perceived negatively by some investors.

Risks

• Insider selling, even when pre-planned, can sometimes be interpreted by the market as a lack of confidence or a signal of limited upside, potentially leading to negative sentiment or short-term share price pressure.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing details an individual insider transaction and does not provide broader industry context or trends.

Corporate Governance

Stakeholder Impact

• Shareholders may note the director's decision to sell shares, but the pre-planned nature under Rule 10b5-1 typically mitigates concerns about opportunistic selling. The director still retains a significant holding of 13,554 shares.

Key Dates

Keywords

Veracyte, VCYT, Insider Trading, Form 4, Stock Options, Share Sale, Director, Rule 10b5-1 Plan